Remdesivir (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Remdesivir" in English language version.

refsWebsite

Global rank English rank

108web.archive.org

1^st place

51nih.gov

4^th place

27doi.org

2^nd place

16fda.gov

447^th place

338^th place

8europa.eu

68^th place

117^th place

7reuters.com

49^th place

47^th place

6tga.gov.au

3,984^th place

2,622^nd place

5gilead.com

low place

5statnews.com

8,771^st place

5,253^rd place

4nytimes.com

7^th place

4semanticscholar.org

11^th place

8^th place

4espacenet.com

800^th place

676^th place

4canada.ca

1,712^th place

1,063^rd place

3harvard.edu

18^th place

17^th place

3clinicaltrials.gov

5,225^th place

4,062^nd place

3theguardian.com

12^th place

11^th place

2medicines.org.uk

3,823^rd place

2,387^th place

2businesswire.com

615^th place

407^th place

2worldcat.org

5^th place

2abc.net.au

139^th place

108^th place

2washingtonpost.com

34^th place

27^th place

2hhs.gov

5,973^rd place

3,693^rd place

2handle.net

102^nd place

76^th place

2indiatimes.com

17^th place

15^th place

1funnelback.com

low place

1hres.ca

low place

1drugs.com

399^th place

333^rd place

1science.org

1,160^th place

737^th place

1oup.com

485^th place

440^th place

1medpagetoday.com

9,274^th place

5,856^th place

1bmj.com

1,226^th place

1,421^st place

1covid19-druginteractions.org

low place

1bloomberg.com

99^th place

77^th place

1drug-dev.com

low place

1bbc.com

20^th place

30^th place

1pharmaceutical-technology.com

low place

1asahi.com

141^st place

1,030^th place

1nationalpost.com

818^th place

524^th place

1cbc.ca

115^th place

82^nd place

1theglobeandmail.com

293^rd place

203^rd place

1globalnews.ca

985^th place

583^rd place

1mzcr.cz

low place

1isna.ir

422^nd place

5,832^nd place

1gob.mx

3,255^th place

4,809^th place

1businessinsider.com

140^th place

115^th place

1hopkinsguides.com

low place

1cbsnews.com

108^th place

80^th place

1acs.org

1,248^th place

1,104^th place

1axios.com

1,716^th place

973^rd place

1voanews.com

581^st place

738^th place

1wsj.com

79^th place

65^th place

1marketwatch.com

1,303^rd place

808^th place

1rmx.news

low place

1keionline.org

low place

1uab.edu

low place

1army.mil

249^th place

169^th place

1who.int

195^th place

302^nd place

1ucdavis.edu

1,873^rd place

1,347^th place

1vettimes.co.uk

low place

abc.net.au

"Remdesivir approved by the Therapeutic Goods Administration for severe coronavirus cases". Australian Broadcasting Corporation. 11 July 2020. Archived from the original on 11 July 2020. Retrieved 11 July 2020.
Hitch G (1 July 2020). "Australia has enough coronavirus drug remdesivir thanks to early supply donation, Health Minister says". Australian Broadcasting Corporation. Archived from the original on 11 July 2020. Retrieved 11 July 2020.

acs.org

cen.acs.org

Jarvis LM (20 April 2020). "Scaling up remdesivir amid the coronavirus crisis". Chemical and Engineering News. Archived from the original on 5 May 2020. Retrieved 2 May 2020.

army.mil

usamriid.army.mil

Antiviral Compound Provides Full Protection from Ebola Virus in Nonhuman Primates (PDF) (Report). United States Army Medical Research Institute of Infectious Diseases (USAMRIID). 9 October 2015. Archived (PDF) from the original on 24 December 2016. Retrieved 15 March 2020.

asahi.com

"Japan approves remdesivir for COVID-19 despite uncertainties". The Asahi Shimbun. 8 May 2020. Archived from the original on 25 May 2020. Retrieved 9 May 2020.

axios.com

Swan J (8 May 2020). "Scoop: Trump officials' dysfunction harms delivery of coronavirus drug". Axios. Archived from the original on 12 May 2020. Retrieved 11 May 2020.

bbc.com

"India, Pakistan to make drug to 'fight coronavirus'". BBC News Online. 14 May 2020. Archived from the original on 28 May 2020. Retrieved 23 May 2020.

bloomberg.com

Langreth R (14 May 2020). "All Eyes on Gilead". Bloomberg Businessweek. Archived from the original on 21 May 2020. Retrieved 14 May 2020.

bmj.com

Ferner RE, Aronson JK (April 2020). "Remdesivir in covid-19". BMJ. 369: m1610. doi:10.1136/bmj.m1610. PMID 32321732. Archived from the original on 8 March 2021. Retrieved 30 April 2020.

businessinsider.com

Naftulin J (20 March 2020). "The FDA is allowing two drugs to be used for 'compassionate use' to treat the coronavirus. Here's what that means". Business Insider. Springer. Archived from the original on 1 May 2020. Retrieved 20 March 2020.

businesswire.com

"Gilead Announces Approval of Veklury (remdesivir) in Japan for Patients With Severe COVID-19" (Press release). Gilead Sciences. 7 May 2020. Archived from the original on 26 June 2020. Retrieved 25 June 2020 – via Business Wire.
"Gilead's Investigational Antiviral Veklury (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19" (Press release). Gilead Sciences. 28 August 2020. Archived from the original on 3 September 2020. Retrieved 28 August 2020 – via Business Wire.

canada.ca

"Coronavirus disease (COVID-19): For health professionals". Public Health Agency of Canada. 11 April 2020. Archived from the original on 11 April 2020. Retrieved 12 April 2020. Gilead is transitioning the provision of emergency access to remdesivir from individual compassionate use via Health Canada's Special Access Program requests to access through clinical trials.
Public Health Canada (23 November 2020). "Ad-hoc COVID-19 Clinical Pharmacology Task Group: Statement on remdesivir". Government of Canada. Archived from the original on 27 December 2020. Retrieved 1 April 2022.

health-products.canada.ca

"Veklury Product information". Health Canada. 25 April 2012. Archived from the original on 26 October 2020. Retrieved 22 October 2020.

covid-vaccine.canada.ca

"Veklury (remdesivir)". COVID-19 vaccines and treatments portal. 27 July 2020. Archived from the original on 1 June 2022. Retrieved 31 May 2022.

cbc.ca

Weikle B (28 July 2020). "Health Canada authorizes drug remdesivir for severe COVID-19 cases". CBC News. Archived from the original on 11 October 2020. Retrieved 10 October 2020.

cbsnews.com

Cerullo M (23 March 2020). "Gilead suspends emergency access to experimental coronavirus drug remdesivir". CBS News. Archived from the original on 21 April 2020. Retrieved 23 March 2020.

clinicaltrials.gov

"Adaptive COVID-19 Treatment Trial (ACTT)". ClinicalTrials.gov. 21 February 2020. Archived from the original on 20 May 2020. Retrieved 11 May 2020.
"Adaptive COVID-19 Treatment Trial 2 (ACTT-2)". ClinicalTrials.gov. 26 May 2020. Archived from the original on 5 August 2020. Retrieved 6 August 2020.
"Adaptive COVID-19 Treatment Trial 3 (ACTT-3)". ClinicalTrials.gov. 30 July 2020. Archived from the original on 6 October 2020. Retrieved 5 August 2020.

covid19-druginteractions.org

"COVID-19 interactions". University of Liverpool. Archived from the original on 28 April 2020. Retrieved 28 April 2020.

doi.org

Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. (April 2020). "Current pharmacological treatments for COVID-19: What's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. eISSN 1476-5381. PMC 7264618. PMID 32329520.
Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A (July 2020). "Pharmacotherapy in COVID-19; A narrative review for emergency providers". The American Journal of Emergency Medicine. 38 (7): 1488–1493. doi:10.1016/j.ajem.2020.04.035. eISSN 0735-6757. PMC 7158837. PMID 32336586.
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (March 2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–5. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMC 5551389. PMID 26934220.
Kupferschmidt K, Cohen J (22 March 2020). "WHO launches global megatrial of the four most promising coronavirus treatments". Science Magazine. doi:10.1126/science.abb8497. S2CID 216325781. Archived from the original on 14 September 2020. Retrieved 27 March 2020.
Mozaffari E, Chandak A, Gottlieb RL, Chima-Melton C, Berry M, Oppelt T, et al. (2024). "Lower mortality risk associated with remdesivir + dexamethasone versus dexamethasone alone for the treatment of patients hospitalized for COVID-19". Clinical Infectious Diseases. doi:10.1093/cid/ciae477. PMID 39302162.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. (May 2020). "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial". Lancet. 395 (10236): 1569–1578. doi:10.1016/S0140-6736(20)31022-9. PMC 7190303. PMID 32423584.
Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. (May 2020). "Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19". ACS Central Science. 6 (5): 672–683. doi:10.1021/acscentsci.0c00489. PMC 7202249. PMID 32483554.
Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. (June 2017). "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses". Science Translational Medicine. 9 (396): eaal3653. doi:10.1126/scitranslmed.aal3653. PMC 5567817. PMID 28659436.
Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. (May 2020). "Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency". The Journal of Biological Chemistry. 295 (20): 6785–6797. doi:10.1074/jbc.RA120.013679. PMC 7242698. PMID 32284326.
Cho A, Saunders OL, Butler T, Zhang L, Xu J, Vela JE, et al. (April 2012). "Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides". Bioorganic & Medicinal Chemistry Letters. 22 (8): 2705–2707. doi:10.1016/j.bmcl.2012.02.105. PMC 7126871. PMID 22446091.
Ferner RE, Aronson JK (April 2020). "Remdesivir in covid-19". BMJ. 369: m1610. doi:10.1136/bmj.m1610. PMID 32321732. Archived from the original on 8 March 2021. Retrieved 30 April 2020.
Tchesnokov EP, Feng JY, Porter DP, Götte M (April 2019). "Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir". Viruses. 11 (4): 326. doi:10.3390/v11040326. PMC 6520719. PMID 30987343.
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M (April 2020). "The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus". The Journal of Biological Chemistry. 295 (15): 4773–4779. doi:10.1074/jbc.AC120.013056. PMC 7152756. PMID 32094225.
Yan VC, Muller FL (July 2020). "Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment". ACS Medicinal Chemistry Letters. 11 (7): 1361–1366. doi:10.1021/acsmedchemlett.0c00316. PMC 7315846. PMID 32665809. S2CID 220056568.
Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. (April 2020). "Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2". Journal of the Pediatric Infectious Diseases Society. 9 (6): 701–715. doi:10.1093/jpids/piaa045. PMC 7188128. PMID 32318706.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. (March 2020). "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro". Cell Research. 30 (3): 269–71. doi:10.1038/s41422-020-0282-0. PMC 7054408. PMID 32020029.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. (June 2020). "Compassionate Use of Remdesivir for Patients with Severe Covid-19". N Engl J Med. 382 (24): 2327–2336. doi:10.1056/NEJMoa2007016. PMC 7169476. PMID 32275812.
Cohen J (27 October 2020). "The 'very, very bad look' of remdesivir, the first FDA-approved COVID-19 drug". Science. doi:10.1126/science.abf4549. S2CID 228932543.
Hill A, Wang J, Levi J, Heath K, Fortunak J (April 2020). "Minimum costs to manufacture new treatments for COVID-19". Journal of Virus Eradication. 6 (2): 61–69. doi:10.1016/S2055-6640(20)30018-2. PMC 7331548. PMID 32405423.
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (March 2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–385. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMC 5551389. PMID 26934220.
Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, et al. (March 2017). "GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses". Scientific Reports. 7: 43395. Bibcode:2017NatSR...743395L. doi:10.1038/srep43395. PMC 5338263. PMID 28262699.
Cao YC, Deng QX, Dai SX (April 2020). "Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence". Travel Medicine and Infectious Disease. 35: 101647. doi:10.1016/j.tmaid.2020.101647. PMC 7151266. PMID 32247927.
Lamontagne F, Agoritsas T, Macdonald H, Leo YS, Diaz J, Agarwal A, et al. (September 2020). "A living WHO guideline on drugs for covid-19". BMJ. 370: m3379. doi:10.1136/bmj.m3379. PMID 32887691.
Ali K, Azher T, Baqi M, Binnie A, Borgia S, Carrier FM, et al. (January 2022). "Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial". Canadian Medical Association Journal. 194 (7): E242–E251. doi:10.1503/cmaj.211698. PMC 8863204. PMID 35045989.
Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. (September 2020). "A living WHO guideline on drugs for covid-19". BMJ. 370: m3379. doi:10.1136/bmj.m3379. PMID 32887691. S2CID 221498813.
Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. (January 2022). "Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients". The New England Journal of Medicine. 386 (4): 305–315. doi:10.1056/NEJMoa2116846. PMC 8757570. PMID 34937145.
Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, et al. (April 2019). "Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis". Journal of Feline Medicine and Surgery. 21 (4): 271–281. doi:10.1177/1098612X19825701. PMC 6435921. PMID 30755068.

drug-dev.com

Pipkin J, Antle V, Garcia-Fandiño R (June 2020). "FORMULATION FORUM – Application of Captisol Technology to Enable the Formulation of Remdesivir in Treating COVID-19". Drug Development & Delivery. Archived from the original on 20 July 2020. Retrieved 20 July 2020.

drugs.com

"Remdesivir". Drugs.com. 20 April 2020. Archived from the original on 16 April 2020. Retrieved 30 April 2020.

espacenet.com

worldwide.espacenet.com

US 9724360, Chun BK, Clarke MO, Doerffler E, Hui HC, Jordan R, Mackman RL, Parrish JP, Ray AS, Siegel D, "Methods for treating Filoviridae virus infections", published 5 May 2016, issued 8 August 2017, assigned to Gilead Sciences Inc.
WO 2017184668, Clarke MO, Jordan R, Mackman RL, Ray AS, Siegel D, "Preparation of amino acid-containing nucleosides for treating flaviviridae virus infections", published 26 October 2017, assigned to Glead Sciences Inc
US 10251898, Chun BK, Clarke MO, Doerffler E, Hui HC, Jordan R, Mackman RL, Parrish JP, Ray AS, Siegel D, "Methods for treating Filoviridae virus infections", published 1 November 2018, issued 9 April 2019, assigned to Gilead Sciences, Inc.
US 10251904, Clarke MO, Feng JY, Jordan R, Mackman RL, Ray AS, Siegel D, "Methods for treating arenaviridae and coronaviridae virus infections", published 16 March 2017, issued 9 April 2019, assigned to Gilead Sciences, Inc.

europa.eu

ema.europa.eu

"Veklury EPAR". European Medicines Agency (EMA). 23 June 2020. Archived from the original on 18 March 2021. Retrieved 8 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"COVID-19 medicines". European Medicines Agency (EMA). 14 October 2024. Retrieved 14 October 2024.
"Summary on Compassionate Use: Remdesivir Gilead" (PDF). European Medicines Agency (EMA). 3 April 2020. Archived (PDF) from the original on 11 April 2020. Retrieved 1 May 2020.
"EU/3/16/1615". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 9 July 2020. Retrieved 7 July 2020. This article incorporates text from this source, which is in the public domain.
"EMA provides recommendations on compassionate use of remdesivir for COVID-19" (Press release). European Medicines Agency (EMA). 3 April 2020. Archived from the original on 19 May 2020. Retrieved 3 May 2020.
"EMA recommends expanding remdesivir compassionate use to patients not on mechanical ventilation" (Press release). European Medicines Agency (EMA). 11 May 2020. Archived from the original on 17 May 2020. Retrieved 11 May 2020. This article incorporates text from this source, which is in the public domain.
"COVID-19 treatments: authorised". European Medicines Agency (EMA). 8 August 2022. Archived from the original on 13 August 2022. Retrieved 12 August 2022.

ec.europa.eu

"Veklury". European Commission. Archived from the original on 22 January 2021. Retrieved 12 August 2022.

fda.gov

"FDA EUA Remdesivir Fact Sheet for Health Care Providers" (PDF). U.S. Food and Drug Administration (FDA). January 2022. Archived from the original on 24 January 2022. Retrieved 23 January 2022. This article incorporates text from this source, which is in the public domain.
"New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Archived from the original on 18 January 2021. Retrieved 17 January 2021. This article incorporates text from this source, which is in the public domain.
"Coronavirus (COVID-19) Update: FDA Approves First COVID-19 Treatment for Young Children" (Press release). U.S. Food and Drug Administration (FDA). 25 April 2022. Archived from the original on 26 April 2022. Retrieved 27 April 2022. This article incorporates text from this source, which is in the public domain.
"Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19" (Press release). U.S. Food and Drug Administration (FDA). 19 November 2020. Archived from the original on 19 November 2020. Retrieved 19 November 2020. This article incorporates text from this source, which is in the public domain.
"Frequently Asked Questions on the Emergency Use Authorization for Remdesivir for Certain Hospitalized COVID-19 Patients" (PDF). U.S. Food and Drug Administration (FDA). 1 May 2020. Archived from the original on 6 May 2020. Retrieved 1 May 2020. This article incorporates text from this source, which is in the public domain.
"Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use" (Press release). U.S. Food and Drug Administration (FDA). 15 June 2020. Archived from the original on 13 October 2020. Retrieved 15 June 2020. This article incorporates text from this source, which is in the public domain.
"Remdesivir EUA Letter of Authorization" (PDF). U.S. Food and Drug Administration (FDA). 1 May 2020. Archived from the original on 2 May 2020. Retrieved 1 May 2020. This article incorporates text from this source, which is in the public domain.
"Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment" (Press release). U.S. Food and Drug Administration (FDA). 1 May 2020. Archived from the original on 11 October 2020. Retrieved 1 May 2020.
"FDA Approves First Treatment for COVID-19" (Press release). U.S. Food and Drug Administration (FDA). 22 October 2020. Archived from the original on 22 October 2020. Retrieved 22 October 2020. This article incorporates text from this source, which is in the public domain.
"COVID-19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 28 August 2020. Archived from the original on 29 August 2020. Retrieved 28 August 2020. This article incorporates text from this source, which is in the public domain.
"FDA's approval of Veklury (remdesivir) for the treatment of COVID-19". U.S. Food and Drug Administration (FDA). 22 October 2020. Archived from the original on 22 October 2020. Retrieved 23 October 2020. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshots: Veklury". U.S. Food and Drug Administration (FDA). 27 October 2020. Archived from the original on 14 July 2021. Retrieved 27 October 2020. This article incorporates text from this source, which is in the public domain.
"FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19" (Press release). U.S. Food and Drug Administration (FDA)_. 21 January 2022. Archived from the original on 24 January 2022. Retrieved 23 January 2022. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Veklury: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 23 October 2020. Retrieved 22 October 2020.
Veklury: Summary Review (PDF). U.S. Food and Drug Administration (FDA) (Report). Archived (PDF) from the original on 23 October 2020. Retrieved 22 October 2020. This article incorporates text from this source, which is in the public domain.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

funnelback.com

tga-search.clients.funnelback.com

"Veklury remdesivir 100 mg powder for injection vial". Therapeutic Goods Administration (TGA). Archived from the original on 23 October 2021. Retrieved 22 October 2021.

gilead.com

"U.S. Food and Drug Administration Approves Gilead's Antiviral Veklury (remdesivir) for Treatment of COVID-19" (Press release). Gilead Sciences, Inc. 22 October 2020. Archived from the original on 23 October 2020. Retrieved 23 October 2020.
"Voluntary Licensing Agreements for Remdesivir". Gilead Sciences, Inc. 24 October 2020. Archived from the original on 11 July 2021. Retrieved 24 October 2020.
"Gilead Sciences Update on Supply and Distribution of Veklury (remdesivir) in the United States". Gilead Sciences (Press release). 1 October 2020. Archived from the original on 29 August 2021. Retrieved 4 October 2020.
"An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences" (Press release). Gilead Sciences. 29 June 2020. Archived from the original on 29 June 2020. Retrieved 29 June 2020.
"Pipeline". Gilead Sciences. 27 February 2020. Archived from the original on 10 April 2013. Retrieved 17 April 2020.

globalnews.ca

Kury de Castillo C (8 October 2020). "Calgary man dies after contracting COVID-19 at Foothills hospital; family seeks remdesivir for daughter on ventilator". Global News. Archived from the original on 10 October 2020. Retrieved 13 October 2020.

gob.mx

"Cofepris emite autorización para uso de emergencia de Remdesivir" [Cofepris Issues Authorization For Emergency Use Of Remdesivir]. Federal Commission for the Protection against Sanitary Risk (Cofepris). 12 March 2020. Archived from the original on 12 March 2021. Retrieved 12 March 2020.

handle.net

hdl.handle.net

World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3): 549. hdl:10665/330961.
World Health Organization (2021). Therapeutics and COVID-19: living guideline, 6 July 2021 (Report). World Health Organization (WHO). hdl:10665/342368. WHO/2019-nCoV/therapeutics/2021.2.

harvard.edu

ui.adsabs.harvard.edu

Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (March 2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–5. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMC 5551389. PMID 26934220.
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (March 2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–385. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMC 5551389. PMID 26934220.
Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, et al. (March 2017). "GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses". Scientific Reports. 7: 43395. Bibcode:2017NatSR...743395L. doi:10.1038/srep43395. PMC 5338263. PMID 28262699.

hhs.gov

"Trump Administration Secures New Supplies of Remdesivir for the United States" (Press release). U.S. Department of Health and Human Services (HHS). 29 June 2020. Archived from the original on 29 June 2020. Retrieved 29 June 2020.
"Veklury (remdesivir) Now Available Directly from Distributor". U.S. Department of Health & Human Services (HHS) (Press release). 1 October 2020. Archived from the original on 27 October 2020. Retrieved 28 October 2020. This article incorporates text from this source, which is in the public domain.

hopkinsguides.com

"Coronavirus COVID-19 (SARS-CoV-2)". Johns Hopkins ABX Guide. Archived from the original on 11 April 2020. Retrieved 12 April 2020. Remdesivir: Likely the most promising drug.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Veklury". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.

indiatimes.com

economictimes.indiatimes.com

Rajagopal D (23 June 2020). "Cipla, Hetero receive drug controller's emergency approval for Remdesivir for severe Covid-19 patients". The Economic Times. Bennett, Coleman & Co. Ltd. Archived from the original on 6 March 2021. Retrieved 1 July 2020.

timesofindia.indiatimes.com

"India approves emergency use of remdesivir to treat Covid-19 patients". The Times of India. Reuters. 2 June 2020. Archived from the original on 4 June 2020. Retrieved 2 June 2020.

isna.ir

"Increasing the production of Remedisivir anti-corona drug by the executive staff of Farman Imam". isna.ir. 7 September 2020. Archived from the original on 25 July 2021.

keionline.org

Ardizzone K (20 March 2020). "Role of the Federal Government in the Development of Remdesivir" (PDF). Knowledge Ecology International. Archived (PDF) from the original on 27 May 2020. Retrieved 28 May 2020.

marketwatch.com

Saigol L (8 October 2020). "Gilead Sciences agrees to sell to Europe up to 500,000 courses of remdesivir". MarketWatch. Archived from the original on 8 October 2020. Retrieved 9 October 2020.

medicines.org.uk

"Veklury 100 mg concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). 6 July 2020. Archived from the original on 24 November 2020. Retrieved 4 October 2020.
"Veklury 100 mg powder for concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 8 October 2020. Retrieved 4 October 2020.

medpagetoday.com

"Remdesivir-Dexamethasone Tied to Fewer Deaths in Severe COVID". MedPage Today. 27 September 2024.

mzcr.cz

"Opatření MZ ČR – povolení LP Remdesivir" [Measures of the Ministry of Health of the Czech Republic – LP Remdesivir permit] (PDF). www.mzcr.cz (in Czech). 17 March 2020. Archived (PDF) from the original on 4 August 2020. Retrieved 24 March 2020.

nationalpost.com

Blackwell T (1 May 2020). "Canadian experts don't see Remdesivir as a COVID-19 killer: 'This is not a silver bullet'". National Post. Retrieved 11 July 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. (April 2020). "Current pharmacological treatments for COVID-19: What's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. eISSN 1476-5381. PMC 7264618. PMID 32329520.
Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A (July 2020). "Pharmacotherapy in COVID-19; A narrative review for emergency providers". The American Journal of Emergency Medicine. 38 (7): 1488–1493. doi:10.1016/j.ajem.2020.04.035. eISSN 0735-6757. PMC 7158837. PMID 32336586.
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (March 2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–5. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMC 5551389. PMID 26934220.
Mozaffari E, Chandak A, Gottlieb RL, Chima-Melton C, Berry M, Oppelt T, et al. (2024). "Lower mortality risk associated with remdesivir + dexamethasone versus dexamethasone alone for the treatment of patients hospitalized for COVID-19". Clinical Infectious Diseases. doi:10.1093/cid/ciae477. PMID 39302162.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. (May 2020). "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial". Lancet. 395 (10236): 1569–1578. doi:10.1016/S0140-6736(20)31022-9. PMC 7190303. PMID 32423584.
Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. (May 2020). "Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19". ACS Central Science. 6 (5): 672–683. doi:10.1021/acscentsci.0c00489. PMC 7202249. PMID 32483554.
Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. (June 2017). "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses". Science Translational Medicine. 9 (396): eaal3653. doi:10.1126/scitranslmed.aal3653. PMC 5567817. PMID 28659436.
Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. (May 2020). "Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency". The Journal of Biological Chemistry. 295 (20): 6785–6797. doi:10.1074/jbc.RA120.013679. PMC 7242698. PMID 32284326.
Cho A, Saunders OL, Butler T, Zhang L, Xu J, Vela JE, et al. (April 2012). "Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides". Bioorganic & Medicinal Chemistry Letters. 22 (8): 2705–2707. doi:10.1016/j.bmcl.2012.02.105. PMC 7126871. PMID 22446091.
Ferner RE, Aronson JK (April 2020). "Remdesivir in covid-19". BMJ. 369: m1610. doi:10.1136/bmj.m1610. PMID 32321732. Archived from the original on 8 March 2021. Retrieved 30 April 2020.
Tchesnokov EP, Feng JY, Porter DP, Götte M (April 2019). "Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir". Viruses. 11 (4): 326. doi:10.3390/v11040326. PMC 6520719. PMID 30987343.
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M (April 2020). "The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus". The Journal of Biological Chemistry. 295 (15): 4773–4779. doi:10.1074/jbc.AC120.013056. PMC 7152756. PMID 32094225.
Yan VC, Muller FL (July 2020). "Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment". ACS Medicinal Chemistry Letters. 11 (7): 1361–1366. doi:10.1021/acsmedchemlett.0c00316. PMC 7315846. PMID 32665809. S2CID 220056568.
Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. (April 2020). "Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2". Journal of the Pediatric Infectious Diseases Society. 9 (6): 701–715. doi:10.1093/jpids/piaa045. PMC 7188128. PMID 32318706.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. (March 2020). "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro". Cell Research. 30 (3): 269–71. doi:10.1038/s41422-020-0282-0. PMC 7054408. PMID 32020029.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. (June 2020). "Compassionate Use of Remdesivir for Patients with Severe Covid-19". N Engl J Med. 382 (24): 2327–2336. doi:10.1056/NEJMoa2007016. PMC 7169476. PMID 32275812.
Hill A, Wang J, Levi J, Heath K, Fortunak J (April 2020). "Minimum costs to manufacture new treatments for COVID-19". Journal of Virus Eradication. 6 (2): 61–69. doi:10.1016/S2055-6640(20)30018-2. PMC 7331548. PMID 32405423.
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (March 2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–385. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMC 5551389. PMID 26934220.
Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, et al. (March 2017). "GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses". Scientific Reports. 7: 43395. Bibcode:2017NatSR...743395L. doi:10.1038/srep43395. PMC 5338263. PMID 28262699.
Cao YC, Deng QX, Dai SX (April 2020). "Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence". Travel Medicine and Infectious Disease. 35: 101647. doi:10.1016/j.tmaid.2020.101647. PMC 7151266. PMID 32247927.
Lamontagne F, Agoritsas T, Macdonald H, Leo YS, Diaz J, Agarwal A, et al. (September 2020). "A living WHO guideline on drugs for covid-19". BMJ. 370: m3379. doi:10.1136/bmj.m3379. PMID 32887691.
Ali K, Azher T, Baqi M, Binnie A, Borgia S, Carrier FM, et al. (January 2022). "Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial". Canadian Medical Association Journal. 194 (7): E242–E251. doi:10.1503/cmaj.211698. PMC 8863204. PMID 35045989.
Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. (September 2020). "A living WHO guideline on drugs for covid-19". BMJ. 370: m3379. doi:10.1136/bmj.m3379. PMID 32887691. S2CID 221498813.
Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. (January 2022). "Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients". The New England Journal of Medicine. 386 (4): 305–315. doi:10.1056/NEJMoa2116846. PMC 8757570. PMID 34937145.
Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, et al. (April 2019). "Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis". Journal of Feline Medicine and Surgery. 21 (4): 271–281. doi:10.1177/1098612X19825701. PMC 6435921. PMID 30755068.

ncbi.nlm.nih.gov

Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. (April 2020). "Current pharmacological treatments for COVID-19: What's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. eISSN 1476-5381. PMC 7264618. PMID 32329520.
Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A (July 2020). "Pharmacotherapy in COVID-19; A narrative review for emergency providers". The American Journal of Emergency Medicine. 38 (7): 1488–1493. doi:10.1016/j.ajem.2020.04.035. eISSN 0735-6757. PMC 7158837. PMID 32336586.
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (March 2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–5. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMC 5551389. PMID 26934220.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. (May 2020). "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial". Lancet. 395 (10236): 1569–1578. doi:10.1016/S0140-6736(20)31022-9. PMC 7190303. PMID 32423584.
Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. (May 2020). "Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19". ACS Central Science. 6 (5): 672–683. doi:10.1021/acscentsci.0c00489. PMC 7202249. PMID 32483554.
Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. (June 2017). "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses". Science Translational Medicine. 9 (396): eaal3653. doi:10.1126/scitranslmed.aal3653. PMC 5567817. PMID 28659436.
Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. (May 2020). "Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency". The Journal of Biological Chemistry. 295 (20): 6785–6797. doi:10.1074/jbc.RA120.013679. PMC 7242698. PMID 32284326.
Cho A, Saunders OL, Butler T, Zhang L, Xu J, Vela JE, et al. (April 2012). "Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides". Bioorganic & Medicinal Chemistry Letters. 22 (8): 2705–2707. doi:10.1016/j.bmcl.2012.02.105. PMC 7126871. PMID 22446091.
Tchesnokov EP, Feng JY, Porter DP, Götte M (April 2019). "Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir". Viruses. 11 (4): 326. doi:10.3390/v11040326. PMC 6520719. PMID 30987343.
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M (April 2020). "The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus". The Journal of Biological Chemistry. 295 (15): 4773–4779. doi:10.1074/jbc.AC120.013056. PMC 7152756. PMID 32094225.
Yan VC, Muller FL (July 2020). "Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment". ACS Medicinal Chemistry Letters. 11 (7): 1361–1366. doi:10.1021/acsmedchemlett.0c00316. PMC 7315846. PMID 32665809. S2CID 220056568.
Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. (April 2020). "Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2". Journal of the Pediatric Infectious Diseases Society. 9 (6): 701–715. doi:10.1093/jpids/piaa045. PMC 7188128. PMID 32318706.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. (March 2020). "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro". Cell Research. 30 (3): 269–71. doi:10.1038/s41422-020-0282-0. PMC 7054408. PMID 32020029.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. (June 2020). "Compassionate Use of Remdesivir for Patients with Severe Covid-19". N Engl J Med. 382 (24): 2327–2336. doi:10.1056/NEJMoa2007016. PMC 7169476. PMID 32275812.
Hill A, Wang J, Levi J, Heath K, Fortunak J (April 2020). "Minimum costs to manufacture new treatments for COVID-19". Journal of Virus Eradication. 6 (2): 61–69. doi:10.1016/S2055-6640(20)30018-2. PMC 7331548. PMID 32405423.
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (March 2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–385. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMC 5551389. PMID 26934220.
Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, et al. (March 2017). "GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses". Scientific Reports. 7: 43395. Bibcode:2017NatSR...743395L. doi:10.1038/srep43395. PMC 5338263. PMID 28262699.
Cao YC, Deng QX, Dai SX (April 2020). "Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence". Travel Medicine and Infectious Disease. 35: 101647. doi:10.1016/j.tmaid.2020.101647. PMC 7151266. PMID 32247927.
Ali K, Azher T, Baqi M, Binnie A, Borgia S, Carrier FM, et al. (January 2022). "Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial". Canadian Medical Association Journal. 194 (7): E242–E251. doi:10.1503/cmaj.211698. PMC 8863204. PMID 35045989.
Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. (January 2022). "Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients". The New England Journal of Medicine. 386 (4): 305–315. doi:10.1056/NEJMoa2116846. PMC 8757570. PMID 34937145.
Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, et al. (April 2019). "Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis". Journal of Feline Medicine and Surgery. 21 (4): 271–281. doi:10.1177/1098612X19825701. PMC 6435921. PMID 30755068.

niaid.nih.gov

"NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19" (Press release). National Institute of Allergy and Infectious Diseases. 29 April 2020. Archived from the original on 30 April 2020. Retrieved 29 April 2020. This article incorporates text from this source, which is in the public domain.
"NIH Clinical Trial Testing Antiviral Remdesivir Plus Anti-Inflammatory Drug Baricitinib for COVID-19 Begins". National Institute of Allergy and Infectious Diseases (NIAID) (Press release). 8 May 2020. Archived from the original on 6 October 2020. Retrieved 5 August 2020. This article incorporates text from this source, which is in the public domain.
"NIH Clinical Trial Testing Remdesivir Plus Interferon Beta-1a for COVID-19 Treatment Begins". National Institute of Allergy and Infectious Diseases (NIAID) (Press release). 30 July 2020. Archived from the original on 6 October 2020. Retrieved 5 August 2020. This article incorporates text from this source, which is in the public domain.

dailymed.nlm.nih.gov

"Veklury- remdesivir injection Veklury- remdesivir injection, powder, lyophilized, for solution". DailyMed. 20 June 2023. Archived from the original on 14 July 2023. Retrieved 14 July 2023.

nih.gov

"Final report confirms remdesivir benefits for COVID-19". National Institutes of Health (NIH) (Press release). 19 October 2020. Archived from the original on 22 October 2020. Retrieved 23 October 2020.

nytimes.com

Stephens B (18 April 2020). "The Story of Remdesivir". The New York Times. p. A23. Archived from the original on 22 May 2020. Retrieved 11 May 2020.
"U.S. Emergency Approval Broadens Use of Gilead's COVID-19 Drug Remdesivir". The New York Times. Reuters. 1 May 2020. Archived from the original on 2 May 2020. Retrieved 1 May 2020.
Kolata G (8 May 2020). "Haphazard Rollout of Coronavirus Drug Frustrates Doctors". The New York Times. Archived from the original on 8 May 2020. Retrieved 8 May 2020.
Kolata G (29 June 2020). "Remdesivir, the First Coronavirus Drug, Gets a Price Tag". The New York Times. Archived from the original on 29 June 2020. Retrieved 29 June 2020.

oup.com

academic.oup.com

Mozaffari E, Chandak A, Gottlieb RL, Chima-Melton C, Berry M, Oppelt T, et al. (2024). "Lower mortality risk associated with remdesivir + dexamethasone versus dexamethasone alone for the treatment of patients hospitalized for COVID-19". Clinical Infectious Diseases. doi:10.1093/cid/ciae477. PMID 39302162.

pharmaceutical-technology.com

"Japanese regulator approves Gilead's remdesivir to treat Covid-19". pharmaceutical-technology.com. 8 May 2020. Archived from the original on 8 January 2021. Retrieved 18 January 2022.

reuters.com

"Singapore approves remdesivir drug for emergency COVID-19 treatment". Reuters. 10 June 2020. Archived from the original on 10 June 2020. Retrieved 10 June 2020.
"Mexico will not follow FDA in approving Gilead's COVID-19 drug". Reuters. 23 October 2020. Archived from the original on 30 October 2020. Retrieved 25 October 2020.
Holland S, Beasley D (4 May 2020). "U.S. emergency approval broadens use of Gilead's COVID-19 drug remdesivir". Reuters. Archived from the original on 11 May 2020. Retrieved 8 May 2020.
Rinke A (1 July 2020). "Germany has for now enough remdesivir for COVID-19 therapy: govt". Reuters. Archived from the original on 1 July 2020. Retrieved 1 July 2020.
Stout A, Mason J (1 July 2020). "UK emergency remdesivir supplies adequate to treat COVID-19, official says". Reuters. Archived from the original on 9 March 2021. Retrieved 18 July 2020.
Guarascio F (29 July 2020). "EU buys remdesivir to treat 30,000 COVID patients, seeks more". Reuters. Archived from the original on 31 July 2020. Retrieved 31 July 2020.
Guarascio F (13 October 2020). "EU makes one billion-euro bet on Gilead's COVID drug before trial results". Reuters. Archived from the original on 23 November 2020. Retrieved 13 October 2020.

rmx.news

"Did Czech scientists create the cure for coronavirus?". Czech News Agency (Aktuálně.cz). 5 February 2020. Archived from the original on 13 May 2020.

science.org

Kupferschmidt K, Cohen J (22 March 2020). "WHO launches global megatrial of the four most promising coronavirus treatments". Science Magazine. doi:10.1126/science.abb8497. S2CID 216325781. Archived from the original on 14 September 2020. Retrieved 27 March 2020.

semanticscholar.org

api.semanticscholar.org

Kupferschmidt K, Cohen J (22 March 2020). "WHO launches global megatrial of the four most promising coronavirus treatments". Science Magazine. doi:10.1126/science.abb8497. S2CID 216325781. Archived from the original on 14 September 2020. Retrieved 27 March 2020.
Yan VC, Muller FL (July 2020). "Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment". ACS Medicinal Chemistry Letters. 11 (7): 1361–1366. doi:10.1021/acsmedchemlett.0c00316. PMC 7315846. PMID 32665809. S2CID 220056568.
Cohen J (27 October 2020). "The 'very, very bad look' of remdesivir, the first FDA-approved COVID-19 drug". Science. doi:10.1126/science.abf4549. S2CID 228932543.
Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. (September 2020). "A living WHO guideline on drugs for covid-19". BMJ. 370: m3379. doi:10.1136/bmj.m3379. PMID 32887691. S2CID 221498813.

statnews.com

Yan VC, Muller FL (14 May 2020). "Gilead should ditch remdesivir and focus on its simpler and safer ancestor". Stat. Archived from the original on 12 June 2021. Retrieved 5 July 2020.
Silverman E (12 May 2020). "Gilead signs deals for generic companies to make and sell remdesivir". Stat. Archived from the original on 16 May 2020. Retrieved 12 May 2020.
Facher L (9 May 2020). "Trump administration announces plan to distribute Covid-19 drug amid concerns over allocation". Stat. Archived from the original on 10 May 2020. Retrieved 11 May 2020.
Branswell H (19 May 2020). "Gilead ups its donation of the Covid-19 drug remdesivir". Stat. Archived from the original on 20 December 2020. Retrieved 19 May 2020.
Silverman E (8 May 2020). "U.S. government contributed research to a Gilead remdesivir patent – but didn't get credit". Stat. Archived from the original on 28 May 2020. Retrieved 28 May 2020.

tga.gov.au

"Veklury Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 13 July 2020. Archived from the original on 13 August 2020. Retrieved 16 August 2020.
"AusPAR: Remdesivir". Therapeutic Goods Administration (TGA). 10 May 2022. Archived from the original on 10 May 2022. Retrieved 10 May 2022.
"COVID-19 treatment: Gilead Sciences Pty Ltd, remdesivir (Veklury)". Therapeutic Goods Administration (TGA). 10 July 2020. Archived from the original on 21 October 2021. Retrieved 22 October 2021.
"TGA grants provisional approval to Gilead Sciences Pty Ltd to extend the use of the COVID-19 treatment, Veklury (remdesivir)". Therapeutic Goods Administration (TGA). 6 May 2022. Archived from the original on 6 May 2022. Retrieved 7 May 2022.
"Australia's first COVID treatment approved". Therapeutic Goods Administration (TGA) (Press release). 10 July 2020. Archived from the original on 11 October 2020. Retrieved 11 July 2020.

ebs.tga.gov.au

"Veklury Powder for Injection Product Information". Therapeutic Goods Administration (TGA). 9 June 2021. Archived from the original on 13 September 2020. Retrieved 16 August 2020.

theglobeandmail.com

Grant K, Howlett K (22 September 2020). "Cases could spike sharply if Canadian epidemic stays on current course, Tam warns". The Globe and Mail. Archived from the original on 2 October 2020. Retrieved 10 October 2020.

theguardian.com

Boseley S (30 June 2020). "US buys up world stock of key Covid-19 drug". The Guardian. Archived from the original on 23 June 2021. Retrieved 30 June 2020.
Davey M (1 July 2020). "Gilead donates Covid-19 drug remdesivir to Australia's medical stockpile after US buys up supply". The Guardian. Archived from the original on 1 July 2020. Retrieved 1 July 2020.
Boseley S (20 November 2020). "Remdesivir: don't use drug Trump took for Covid-19, WHO says". The Guardian. Archived from the original on 19 April 2022. Retrieved 23 January 2022.

uab.edu

"Investigational compound remdesivir, developed by UAB and NIH researchers, being used for treatment of novel coronavirus". UAB News. Archived from the original on 26 May 2020. Retrieved 28 May 2020.

ucdavis.edu

ccah.vetmed.ucdavis.edu

Pedersen NC (18 June 2019). "Black market production and sale of GS-441524 and GC376" (PDF). Feline Infectious Peritonitis Therapeutics/Clinical Trials Team, UC Davis. Archived (PDF) from the original on 25 March 2020. Retrieved 14 April 2020.

vettimes.co.uk

Westgate J (7 May 2020). "Vet science 'being ignored' in quest for COVID-19 drug". vettimes.co.uk. Archived from the original on 4 December 2020. Retrieved 6 July 2020.

voanews.com

Baragona S (29 June 2020). "US Procures Almost Entire Supply of COVID-19 Drug". Voice of America. U.S. Agency for Global Media. Archived from the original on 30 June 2020. Retrieved 30 June 2020.

washingtonpost.com

Rowland C (10 April 2020). "Gilead's experimental drug remdesivir shows 'hopeful' signs in small group of coronavirus patients". The Washington Post. Archived from the original on 7 May 2020. Retrieved 8 May 2020.
Abutaleb Y, Dawsey J, Sun LH, McGinley L (28 May 2020). "Administration initially dispensed scarce covid-19 drug to some hospitals that didn't need it". The Washington Post. Archived from the original on 28 May 2020. Retrieved 29 May 2020.

web.archive.org

"Veklury Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 13 July 2020. Archived from the original on 13 August 2020. Retrieved 16 August 2020.
"AusPAR: Remdesivir". Therapeutic Goods Administration (TGA). 10 May 2022. Archived from the original on 10 May 2022. Retrieved 10 May 2022.
"Veklury Powder for Injection Product Information". Therapeutic Goods Administration (TGA). 9 June 2021. Archived from the original on 13 September 2020. Retrieved 16 August 2020.
"Veklury remdesivir 100 mg powder for injection vial". Therapeutic Goods Administration (TGA). Archived from the original on 23 October 2021. Retrieved 22 October 2021.
"COVID-19 treatment: Gilead Sciences Pty Ltd, remdesivir (Veklury)". Therapeutic Goods Administration (TGA). 10 July 2020. Archived from the original on 21 October 2021. Retrieved 22 October 2021.
"Veklury Product information". Health Canada. 25 April 2012. Archived from the original on 26 October 2020. Retrieved 22 October 2020.
"Summary Basis of Decision (SBD) for Veklury". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
"Veklury (remdesivir)". COVID-19 vaccines and treatments portal. 27 July 2020. Archived from the original on 1 June 2022. Retrieved 31 May 2022.
"Veklury 100 mg concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). 6 July 2020. Archived from the original on 24 November 2020. Retrieved 4 October 2020.
"Veklury 100 mg powder for concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 8 October 2020. Retrieved 4 October 2020.
"Veklury- remdesivir injection Veklury- remdesivir injection, powder, lyophilized, for solution". DailyMed. 20 June 2023. Archived from the original on 14 July 2023. Retrieved 14 July 2023.
"Veklury EPAR". European Medicines Agency (EMA). 23 June 2020. Archived from the original on 18 March 2021. Retrieved 8 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Gilead Announces Approval of Veklury (remdesivir) in Japan for Patients With Severe COVID-19" (Press release). Gilead Sciences. 7 May 2020. Archived from the original on 26 June 2020. Retrieved 25 June 2020 – via Business Wire.
"Remdesivir". Drugs.com. 20 April 2020. Archived from the original on 16 April 2020. Retrieved 30 April 2020.
"U.S. Food and Drug Administration Approves Gilead's Antiviral Veklury (remdesivir) for Treatment of COVID-19" (Press release). Gilead Sciences, Inc. 22 October 2020. Archived from the original on 23 October 2020. Retrieved 23 October 2020.
Stephens B (18 April 2020). "The Story of Remdesivir". The New York Times. p. A23. Archived from the original on 22 May 2020. Retrieved 11 May 2020.
Kupferschmidt K, Cohen J (22 March 2020). "WHO launches global megatrial of the four most promising coronavirus treatments". Science Magazine. doi:10.1126/science.abb8497. S2CID 216325781. Archived from the original on 14 September 2020. Retrieved 27 March 2020.
Yan VC, Muller FL (14 May 2020). "Gilead should ditch remdesivir and focus on its simpler and safer ancestor". Stat. Archived from the original on 12 June 2021. Retrieved 5 July 2020.
"FDA EUA Remdesivir Fact Sheet for Health Care Providers" (PDF). U.S. Food and Drug Administration (FDA). January 2022. Archived from the original on 24 January 2022. Retrieved 23 January 2022. This article incorporates text from this source, which is in the public domain.
"New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Archived from the original on 18 January 2021. Retrieved 17 January 2021. This article incorporates text from this source, which is in the public domain.
"Coronavirus (COVID-19) Update: FDA Approves First COVID-19 Treatment for Young Children" (Press release). U.S. Food and Drug Administration (FDA). 25 April 2022. Archived from the original on 26 April 2022. Retrieved 27 April 2022. This article incorporates text from this source, which is in the public domain.
"Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19" (Press release). U.S. Food and Drug Administration (FDA). 19 November 2020. Archived from the original on 19 November 2020. Retrieved 19 November 2020. This article incorporates text from this source, which is in the public domain.
"TGA grants provisional approval to Gilead Sciences Pty Ltd to extend the use of the COVID-19 treatment, Veklury (remdesivir)". Therapeutic Goods Administration (TGA). 6 May 2022. Archived from the original on 6 May 2022. Retrieved 7 May 2022.
"Frequently Asked Questions on the Emergency Use Authorization for Remdesivir for Certain Hospitalized COVID-19 Patients" (PDF). U.S. Food and Drug Administration (FDA). 1 May 2020. Archived from the original on 6 May 2020. Retrieved 1 May 2020. This article incorporates text from this source, which is in the public domain.
Ferner RE, Aronson JK (April 2020). "Remdesivir in covid-19". BMJ. 369: m1610. doi:10.1136/bmj.m1610. PMID 32321732. Archived from the original on 8 March 2021. Retrieved 30 April 2020.
"Summary on Compassionate Use: Remdesivir Gilead" (PDF). European Medicines Agency (EMA). 3 April 2020. Archived (PDF) from the original on 11 April 2020. Retrieved 1 May 2020.
"COVID-19 interactions". University of Liverpool. Archived from the original on 28 April 2020. Retrieved 28 April 2020.
"Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use" (Press release). U.S. Food and Drug Administration (FDA). 15 June 2020. Archived from the original on 13 October 2020. Retrieved 15 June 2020. This article incorporates text from this source, which is in the public domain.
Langreth R (14 May 2020). "All Eyes on Gilead". Bloomberg Businessweek. Archived from the original on 21 May 2020. Retrieved 14 May 2020.
Pipkin J, Antle V, Garcia-Fandiño R (June 2020). "FORMULATION FORUM – Application of Captisol Technology to Enable the Formulation of Remdesivir in Treating COVID-19". Drug Development & Delivery. Archived from the original on 20 July 2020. Retrieved 20 July 2020.
Silverman E (12 May 2020). "Gilead signs deals for generic companies to make and sell remdesivir". Stat. Archived from the original on 16 May 2020. Retrieved 12 May 2020.
"India, Pakistan to make drug to 'fight coronavirus'". BBC News Online. 14 May 2020. Archived from the original on 28 May 2020. Retrieved 23 May 2020.
"Voluntary Licensing Agreements for Remdesivir". Gilead Sciences, Inc. 24 October 2020. Archived from the original on 11 July 2021. Retrieved 24 October 2020.
Rajagopal D (23 June 2020). "Cipla, Hetero receive drug controller's emergency approval for Remdesivir for severe Covid-19 patients". The Economic Times. Bennett, Coleman & Co. Ltd. Archived from the original on 6 March 2021. Retrieved 1 July 2020.
"India approves emergency use of remdesivir to treat Covid-19 patients". The Times of India. Reuters. 2 June 2020. Archived from the original on 4 June 2020. Retrieved 2 June 2020.
"Singapore approves remdesivir drug for emergency COVID-19 treatment". Reuters. 10 June 2020. Archived from the original on 10 June 2020. Retrieved 10 June 2020.
"Japanese regulator approves Gilead's remdesivir to treat Covid-19". pharmaceutical-technology.com. 8 May 2020. Archived from the original on 8 January 2021. Retrieved 18 January 2022.
"Remdesivir EUA Letter of Authorization" (PDF). U.S. Food and Drug Administration (FDA). 1 May 2020. Archived from the original on 2 May 2020. Retrieved 1 May 2020. This article incorporates text from this source, which is in the public domain.
"Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment" (Press release). U.S. Food and Drug Administration (FDA). 1 May 2020. Archived from the original on 11 October 2020. Retrieved 1 May 2020.
"Japan approves remdesivir for COVID-19 despite uncertainties". The Asahi Shimbun. 8 May 2020. Archived from the original on 25 May 2020. Retrieved 9 May 2020.
"Australia's first COVID treatment approved". Therapeutic Goods Administration (TGA) (Press release). 10 July 2020. Archived from the original on 11 October 2020. Retrieved 11 July 2020.
"Veklury: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 23 October 2020. Retrieved 22 October 2020.
Veklury: Summary Review (PDF). U.S. Food and Drug Administration (FDA) (Report). Archived (PDF) from the original on 23 October 2020. Retrieved 22 October 2020. This article incorporates text from this source, which is in the public domain.
"FDA Approves First Treatment for COVID-19" (Press release). U.S. Food and Drug Administration (FDA). 22 October 2020. Archived from the original on 22 October 2020. Retrieved 22 October 2020. This article incorporates text from this source, which is in the public domain.
"Remdesivir approved by the Therapeutic Goods Administration for severe coronavirus cases". Australian Broadcasting Corporation. 11 July 2020. Archived from the original on 11 July 2020. Retrieved 11 July 2020.
Hitch G (1 July 2020). "Australia has enough coronavirus drug remdesivir thanks to early supply donation, Health Minister says". Australian Broadcasting Corporation. Archived from the original on 11 July 2020. Retrieved 11 July 2020.
"Coronavirus disease (COVID-19): For health professionals". Public Health Agency of Canada. 11 April 2020. Archived from the original on 11 April 2020. Retrieved 12 April 2020. Gilead is transitioning the provision of emergency access to remdesivir from individual compassionate use via Health Canada's Special Access Program requests to access through clinical trials.
Weikle B (28 July 2020). "Health Canada authorizes drug remdesivir for severe COVID-19 cases". CBC News. Archived from the original on 11 October 2020. Retrieved 10 October 2020.
Grant K, Howlett K (22 September 2020). "Cases could spike sharply if Canadian epidemic stays on current course, Tam warns". The Globe and Mail. Archived from the original on 2 October 2020. Retrieved 10 October 2020.
Kury de Castillo C (8 October 2020). "Calgary man dies after contracting COVID-19 at Foothills hospital; family seeks remdesivir for daughter on ventilator". Global News. Archived from the original on 10 October 2020. Retrieved 13 October 2020.
"Opatření MZ ČR – povolení LP Remdesivir" [Measures of the Ministry of Health of the Czech Republic – LP Remdesivir permit] (PDF). www.mzcr.cz (in Czech). 17 March 2020. Archived (PDF) from the original on 4 August 2020. Retrieved 24 March 2020.
"EU/3/16/1615". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 9 July 2020. Retrieved 7 July 2020. This article incorporates text from this source, which is in the public domain.
"EMA provides recommendations on compassionate use of remdesivir for COVID-19" (Press release). European Medicines Agency (EMA). 3 April 2020. Archived from the original on 19 May 2020. Retrieved 3 May 2020.
"EMA recommends expanding remdesivir compassionate use to patients not on mechanical ventilation" (Press release). European Medicines Agency (EMA). 11 May 2020. Archived from the original on 17 May 2020. Retrieved 11 May 2020. This article incorporates text from this source, which is in the public domain.
"Adaptive COVID-19 Treatment Trial (ACTT)". ClinicalTrials.gov. 21 February 2020. Archived from the original on 20 May 2020. Retrieved 11 May 2020.
"NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19" (Press release). National Institute of Allergy and Infectious Diseases. 29 April 2020. Archived from the original on 30 April 2020. Retrieved 29 April 2020. This article incorporates text from this source, which is in the public domain.
"Veklury". European Commission. Archived from the original on 22 January 2021. Retrieved 12 August 2022.
"COVID-19 treatments: authorised". European Medicines Agency (EMA). 8 August 2022. Archived from the original on 13 August 2022. Retrieved 12 August 2022.
"Increasing the production of Remedisivir anti-corona drug by the executive staff of Farman Imam". isna.ir. 7 September 2020. Archived from the original on 25 July 2021.
"Mexico will not follow FDA in approving Gilead's COVID-19 drug". Reuters. 23 October 2020. Archived from the original on 30 October 2020. Retrieved 25 October 2020.
"Cofepris emite autorización para uso de emergencia de Remdesivir" [Cofepris Issues Authorization For Emergency Use Of Remdesivir]. Federal Commission for the Protection against Sanitary Risk (Cofepris). 12 March 2020. Archived from the original on 12 March 2021. Retrieved 12 March 2020.
Naftulin J (20 March 2020). "The FDA is allowing two drugs to be used for 'compassionate use' to treat the coronavirus. Here's what that means". Business Insider. Springer. Archived from the original on 1 May 2020. Retrieved 20 March 2020.
"Coronavirus COVID-19 (SARS-CoV-2)". Johns Hopkins ABX Guide. Archived from the original on 11 April 2020. Retrieved 12 April 2020. Remdesivir: Likely the most promising drug.
Cerullo M (23 March 2020). "Gilead suspends emergency access to experimental coronavirus drug remdesivir". CBS News. Archived from the original on 21 April 2020. Retrieved 23 March 2020.
"U.S. Emergency Approval Broadens Use of Gilead's COVID-19 Drug Remdesivir". The New York Times. Reuters. 1 May 2020. Archived from the original on 2 May 2020. Retrieved 1 May 2020.
Holland S, Beasley D (4 May 2020). "U.S. emergency approval broadens use of Gilead's COVID-19 drug remdesivir". Reuters. Archived from the original on 11 May 2020. Retrieved 8 May 2020.
Jarvis LM (20 April 2020). "Scaling up remdesivir amid the coronavirus crisis". Chemical and Engineering News. Archived from the original on 5 May 2020. Retrieved 2 May 2020.
Rowland C (10 April 2020). "Gilead's experimental drug remdesivir shows 'hopeful' signs in small group of coronavirus patients". The Washington Post. Archived from the original on 7 May 2020. Retrieved 8 May 2020.
Kolata G (8 May 2020). "Haphazard Rollout of Coronavirus Drug Frustrates Doctors". The New York Times. Archived from the original on 8 May 2020. Retrieved 8 May 2020.
Swan J (8 May 2020). "Scoop: Trump officials' dysfunction harms delivery of coronavirus drug". Axios. Archived from the original on 12 May 2020. Retrieved 11 May 2020.
Abutaleb Y, Dawsey J, Sun LH, McGinley L (28 May 2020). "Administration initially dispensed scarce covid-19 drug to some hospitals that didn't need it". The Washington Post. Archived from the original on 28 May 2020. Retrieved 29 May 2020.
Facher L (9 May 2020). "Trump administration announces plan to distribute Covid-19 drug amid concerns over allocation". Stat. Archived from the original on 10 May 2020. Retrieved 11 May 2020.
Branswell H (19 May 2020). "Gilead ups its donation of the Covid-19 drug remdesivir". Stat. Archived from the original on 20 December 2020. Retrieved 19 May 2020.
Kolata G (29 June 2020). "Remdesivir, the First Coronavirus Drug, Gets a Price Tag". The New York Times. Archived from the original on 29 June 2020. Retrieved 29 June 2020.
"Trump Administration Secures New Supplies of Remdesivir for the United States" (Press release). U.S. Department of Health and Human Services (HHS). 29 June 2020. Archived from the original on 29 June 2020. Retrieved 29 June 2020.
Boseley S (30 June 2020). "US buys up world stock of key Covid-19 drug". The Guardian. Archived from the original on 23 June 2021. Retrieved 30 June 2020.
Baragona S (29 June 2020). "US Procures Almost Entire Supply of COVID-19 Drug". Voice of America. U.S. Agency for Global Media. Archived from the original on 30 June 2020. Retrieved 30 June 2020.
Davey M (1 July 2020). "Gilead donates Covid-19 drug remdesivir to Australia's medical stockpile after US buys up supply". The Guardian. Archived from the original on 1 July 2020. Retrieved 1 July 2020.
Rinke A (1 July 2020). "Germany has for now enough remdesivir for COVID-19 therapy: govt". Reuters. Archived from the original on 1 July 2020. Retrieved 1 July 2020.
Stout A, Mason J (1 July 2020). "UK emergency remdesivir supplies adequate to treat COVID-19, official says". Reuters. Archived from the original on 9 March 2021. Retrieved 18 July 2020.
"COVID-19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 28 August 2020. Archived from the original on 29 August 2020. Retrieved 28 August 2020. This article incorporates text from this source, which is in the public domain.
"Gilead's Investigational Antiviral Veklury (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19" (Press release). Gilead Sciences. 28 August 2020. Archived from the original on 3 September 2020. Retrieved 28 August 2020 – via Business Wire.
Walker J (1 October 2020). "All Remdesivir Supplies to Be Distributed in U.S. by Maker Gilead Sciences". The Wall Street Journal. Archived from the original on 29 August 2021. Retrieved 4 October 2020.
"Gilead Sciences Update on Supply and Distribution of Veklury (remdesivir) in the United States". Gilead Sciences (Press release). 1 October 2020. Archived from the original on 29 August 2021. Retrieved 4 October 2020.
"Veklury (remdesivir) Now Available Directly from Distributor". U.S. Department of Health & Human Services (HHS) (Press release). 1 October 2020. Archived from the original on 27 October 2020. Retrieved 28 October 2020. This article incorporates text from this source, which is in the public domain.
"FDA's approval of Veklury (remdesivir) for the treatment of COVID-19". U.S. Food and Drug Administration (FDA). 22 October 2020. Archived from the original on 22 October 2020. Retrieved 23 October 2020. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshots: Veklury". U.S. Food and Drug Administration (FDA). 27 October 2020. Archived from the original on 14 July 2021. Retrieved 27 October 2020. This article incorporates text from this source, which is in the public domain.
"FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19" (Press release). U.S. Food and Drug Administration (FDA)_. 21 January 2022. Archived from the original on 24 January 2022. Retrieved 23 January 2022. This article incorporates text from this source, which is in the public domain.
"An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences" (Press release). Gilead Sciences. 29 June 2020. Archived from the original on 29 June 2020. Retrieved 29 June 2020.
Guarascio F (29 July 2020). "EU buys remdesivir to treat 30,000 COVID patients, seeks more". Reuters. Archived from the original on 31 July 2020. Retrieved 31 July 2020.
Saigol L (8 October 2020). "Gilead Sciences agrees to sell to Europe up to 500,000 courses of remdesivir". MarketWatch. Archived from the original on 8 October 2020. Retrieved 9 October 2020.
Guarascio F (13 October 2020). "EU makes one billion-euro bet on Gilead's COVID drug before trial results". Reuters. Archived from the original on 23 November 2020. Retrieved 13 October 2020.
"Pipeline". Gilead Sciences. 27 February 2020. Archived from the original on 10 April 2013. Retrieved 17 April 2020.
"Final report confirms remdesivir benefits for COVID-19". National Institutes of Health (NIH) (Press release). 19 October 2020. Archived from the original on 22 October 2020. Retrieved 23 October 2020.
"Did Czech scientists create the cure for coronavirus?". Czech News Agency (Aktuálně.cz). 5 February 2020. Archived from the original on 13 May 2020.
Silverman E (8 May 2020). "U.S. government contributed research to a Gilead remdesivir patent – but didn't get credit". Stat. Archived from the original on 28 May 2020. Retrieved 28 May 2020.
Ardizzone K (20 March 2020). "Role of the Federal Government in the Development of Remdesivir" (PDF). Knowledge Ecology International. Archived (PDF) from the original on 27 May 2020. Retrieved 28 May 2020.
"Investigational compound remdesivir, developed by UAB and NIH researchers, being used for treatment of novel coronavirus". UAB News. Archived from the original on 26 May 2020. Retrieved 28 May 2020.
Antiviral Compound Provides Full Protection from Ebola Virus in Nonhuman Primates (PDF) (Report). United States Army Medical Research Institute of Infectious Diseases (USAMRIID). 9 October 2015. Archived (PDF) from the original on 24 December 2016. Retrieved 15 March 2020.
"Therapeutics and COVID-19: living guideline". World Health Organization (WHO). 17 January 2022. Archived from the original on 25 March 2021. Retrieved 23 January 2022.
Boseley S (20 November 2020). "Remdesivir: don't use drug Trump took for Covid-19, WHO says". The Guardian. Archived from the original on 19 April 2022. Retrieved 23 January 2022.
Public Health Canada (23 November 2020). "Ad-hoc COVID-19 Clinical Pharmacology Task Group: Statement on remdesivir". Government of Canada. Archived from the original on 27 December 2020. Retrieved 1 April 2022.
"NIH Clinical Trial Testing Antiviral Remdesivir Plus Anti-Inflammatory Drug Baricitinib for COVID-19 Begins". National Institute of Allergy and Infectious Diseases (NIAID) (Press release). 8 May 2020. Archived from the original on 6 October 2020. Retrieved 5 August 2020. This article incorporates text from this source, which is in the public domain.
"NIH Clinical Trial Testing Remdesivir Plus Interferon Beta-1a for COVID-19 Treatment Begins". National Institute of Allergy and Infectious Diseases (NIAID) (Press release). 30 July 2020. Archived from the original on 6 October 2020. Retrieved 5 August 2020. This article incorporates text from this source, which is in the public domain.
"Adaptive COVID-19 Treatment Trial 2 (ACTT-2)". ClinicalTrials.gov. 26 May 2020. Archived from the original on 5 August 2020. Retrieved 6 August 2020.
"Adaptive COVID-19 Treatment Trial 3 (ACTT-3)". ClinicalTrials.gov. 30 July 2020. Archived from the original on 6 October 2020. Retrieved 5 August 2020.
Pedersen NC (18 June 2019). "Black market production and sale of GS-441524 and GC376" (PDF). Feline Infectious Peritonitis Therapeutics/Clinical Trials Team, UC Davis. Archived (PDF) from the original on 25 March 2020. Retrieved 14 April 2020.
Westgate J (7 May 2020). "Vet science 'being ignored' in quest for COVID-19 drug". vettimes.co.uk. Archived from the original on 4 December 2020. Retrieved 6 July 2020.

who.int

"Therapeutics and COVID-19: living guideline". World Health Organization (WHO). 17 January 2022. Archived from the original on 25 March 2021. Retrieved 23 January 2022.

worldcat.org

search.worldcat.org

Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. (April 2020). "Current pharmacological treatments for COVID-19: What's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. eISSN 1476-5381. PMC 7264618. PMID 32329520.
Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A (July 2020). "Pharmacotherapy in COVID-19; A narrative review for emergency providers". The American Journal of Emergency Medicine. 38 (7): 1488–1493. doi:10.1016/j.ajem.2020.04.035. eISSN 0735-6757. PMC 7158837. PMID 32336586.

wsj.com

Walker J (1 October 2020). "All Remdesivir Supplies to Be Distributed in U.S. by Maker Gilead Sciences". The Wall Street Journal. Archived from the original on 29 August 2021. Retrieved 4 October 2020.